113283-93-5

Basic information

• Product Name: TERT-BUTYL 2-(ETHYLAMINO)ETHYLCARBAMATE
• Synonyms: TERT-BUTYL 2-(ETHYLAMINO)ETHYLCARBAMATE;Carbamic acid,[2-(Ethylamino)ethyl]-,1,1-dimethylethyl ester (9CI);tert-Butly 2-(ethylamino)ethylcarbamate;tert-Butyl N-[2-(ethylamino)ethyl]carbamate;1-(Boc-aMino)-2-(ethylaMino)ethane;2-Methyl-2-propanyl [2-(ethylaMino)ethyl]carbaMate;(2-Ethylamino-ethyl)-carbamic acid tert-butyl ester;tert-Butyl (2-(ethylamino)
• CAS NO: 113283-93-5
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.2673
• Mol File: 113283-93-5.mol
• Article Data: 12

Chemical Properties

• Melting Point: 54-55 °C(Solv: pentane (109-66-0))
• Boiling Point: 278℃
• Flash Point: 122℃
• Appearance: /
• Density: 0.949
• Storage Temp.: 2-8°C(protect from light)
• PKA: 13.00±0.46(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2-(ETHYLAMINO)ETHYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2-(ETHYLAMINO)ETHYLCARBAMATE(113283-93-5)
• EPA Substance Registry System: TERT-BUTYL 2-(ETHYLAMINO)ETHYLCARBAMATE(113283-93-5)

Safety Data

• Hazardous Substances Data: 113283-93-5(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-(ethylamino)ethylcarbamate is a synthetic organic compound with the chemical formula C9H20N2O2. It is a carbamate derivative and it is commonly used as a reagent in organic synthesis. This chemical is known to be a stable solid at room temperature, and it has a relatively low toxicity. Tert-butyl 2-(ethylamino)ethylcarbamate has been studied for its potential pharmacological applications, particularly in the fields of neuroscience and drug development. It is important to handle this chemical with caution and adhere to proper safety protocols when working with it in a laboratory setting.

InChI:InChI=1/C9H20N2O2/c1-5-10-6-7-11(8(12)13)9(2,3)4/h10H,5-7H2,1-4H3,(H,12,13)/p-1

Upstream product

• 57260-73-8 N-BOC-1,2-diaminoethane 
• 75-07-0 acetaldehyde 
• 89711-08-0 N-(t-butoxycarbonyl)glycinal 
• 75-04-7 ethylamine 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 110-72-5 N-ethylethane-1,2-diamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13139-12-3 tert-butyl 2,5-dioxopyrrolidin-1-yl carbonate 
• 113283-91-3 N¹,N²-dibenzyloxycarbonyl-N²-tert-butoxycarbonyl-N¹-ethyl-1,2-ethylenediamine 

Downstream Products

• 1104546-97-5 tert-butyl 2-{ethyl-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]amino}ethylcarbamate 
• 1203701-96-5 (2-{[5-(7-chloroquinolin-4-ylamino)2-hydroxybenzyl]-ethylamino}ethyl)carbamic acid tert-butyl ester 
• 135250-93-0 N-(tert-butoxycarbonyl)-2-[ethyl(4-tolylsulfonyl)amino]ethylamine 
• 113283-95-7 N²-Boc-N¹-ethyl-N¹-Z-ethylenediamine 

Relevant articles and documents

Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis

On the basis of a previously discovered anti-αVβ3 integrin peptidomimetic (c(AmpRGD)) and the clinically approved antiangiogenic kinase inhibitor sunitinib, three novel dual conjugates were synthesized (compounds 1-3), featuring the covalent and robust linkage between these two active modules. In all conjugates, the ligand binding competence toward αVβ3 (using both isolated receptors and αVβ3-overexpressing endothelial progenitor EP cells) and the kinase inhibitory activity (toward both isolated kinases and EPCs) remained almost untouched and comparable to the activity of the single active units. Compounds 1-3 showed interesting antiangiogenesis properties in an in vitro tubulogenic assay; furthermore, dimeric-RGD conjugate 3 strongly inhibited in vivo angiogenesis in Matrigel plug assays in FVB mice. These results offer proof-of-concept of how the covalent conjugation of two angiogenesis-related small modules may result in novel and stable molecules, which impair tumor-related angiogenesis with equal or even superior ability as compared to the single modules or their simple combinations.

Polymer-des-ethyl sunitinib conjugates

The invention relates to (among other things) polymer-des-ethyl sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over des-ethyl sunitinib in unconjugated form.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.